P639: OUTCOMES FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA PREVIOUSLY TREATED WITH A COVALENT BTK AND BCL2 INHIBITOR IN THE UNITED STATES: A REAL-WORLD DATABASE STUDY

• A. R. Mato,
• Y. Chen,
• A. C. Girvan,
• L. M. Hess,
• L. Bowman,
• P. Abada,
• H. Konig,
• R. A. Walgren

Affiliations

A. R. Mato

1 Memorial Sloan Kettering Cancer Center, New York

Y. Chen

2 Eli Lilly and Company, Indianapolis, United States of America

A. C. Girvan

2 Eli Lilly and Company, Indianapolis, United States of America

L. M. Hess

2 Eli Lilly and Company, Indianapolis, United States of America

L. Bowman

2 Eli Lilly and Company, Indianapolis, United States of America

P. Abada

2 Eli Lilly and Company, Indianapolis, United States of America

H. Konig

2 Eli Lilly and Company, Indianapolis, United States of America

R. A. Walgren

2 Eli Lilly and Company, Indianapolis, United States of America